Why Tempus AI Stock Is Plunging This Week

Key Points

• Tempus AI specializes in developing artificial intelligence solutions to improve patient outcomes in various healthcare fields.

• Ark Invest reduced the Tempus AI position in the ARK Innovation ETF.

• Tempus AI still holds a significant weighting in the ARK Genomic Revolution ETF.

• 10 stocks we like better than Tempus AI ›

Prior to the start of this week, Tempus AI (NASDAQ: TEM) stock had locked in a 161% gain since the start of the year -- an impressive performance for the healthcare company that's pioneering artificial intelligence (AI) solutions for improving patient outcomes. This week, however, Main Street noted a well-known investor's decision to trim her position in Tempus AI stock, and the stock plunged.

According to data provided by S&P Global Market Intelligence, Tempus AI stock had fallen 12.4% from the end of trading last Friday through the close of Thursday's market session.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

Ark Invest decides it's time to reduce its position in Tempus AI

Representing significant positions in more than one of Ark Invest's exchange-traded funds (ETFs), Tempus AI is ending the week with a smaller weighting in the ARK Innovation ETF (NYSEMKT: ARKK). On Tuesday, Ark Invest trimmed the Tempus AI position in the ARK Innovation ETF by 62,352 shares, a transaction valued at about $5.2 million.

The decision to reduce the weighting of Tempus AI follows soon after the company announced it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device -- a tool intended to support drug development programs.

While the Cathie Wood-led ETF reduced its position in Tempus AI, the stock still retains a significant weighting in the ARK Genomic Revolution ETF, where it's the largest position with a 10.7% weighting as of the end of trading on Thursday.

Should AI investors follow suit and reduce their positions in Tempus AI?

Although investors may be disconcerted to see the ARK Innovation ETF reduce its Tempus AI position, it's worth noting that the AI stock still holds the pole position in the ARK Genomic Revolution ETF, so it's clear Cathie Wood isn't eschewing the stock completely.

Ark Invest ETFs frequently buy and sell stocks, and it wouldn't be surprising if the fund chooses to buy Tempus AI stock again if the stock drops much further. If you were bullish on Tempus AI stock yesterday, nothing should change today.

Should you invest $1,000 in Tempus AI right now?

Before you buy stock in Tempus AI, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $649,280!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,084,802!*

Now, it’s worth noting Stock Advisor’s total average return is 1,058% — a market-crushing outperformance compared to 189% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 22, 2025

Scott Levine has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.